Helix BioPharma (TSE:HBP) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?

Key Points

• Helix BioPharma's share price has crossed above its 200-day moving average, reaching as high as C$2.48 before settling at C$2.13.
• The company holds a market cap of C$162.69 million and has a price-to-earnings ratio of -2.07, indicating a potential emphasis on growth over current profitability.
• Helix BioPharma is focused on cancer drug development in the field of immuno-oncology, with key pipeline candidates including Tumor Defence Breaker L-DOS47 and V-DOS47.

Shares of Helix BioPharma Corp. (TSE:HBP - ) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$1.25 and traded as high as C$2.48. Helix BioPharma shares last traded at C$2.13, with a volume of 6,776 shares changing hands.

Helix BioPharma Stock Performance

The company has a market cap of C$162.69 million, a price-to-earnings ratio of -2.07 and a beta of 0.12. The business's 50 day moving average price is C$1.86 and its 200-day moving average price is C$1.25.

About Helix BioPharma

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.